POZEN Logo
Print Page   Close Window

2009 Press Releases

DateTitle 
December 03, 2009POZEN to Host Investor and Analyst Event on December 8, 2009Printer Friendly Version
November 20, 2009POZEN Announces Start of Enrollment For PA32540 Phase 3 ProgramPrinter Friendly Version
October 30, 2009POZEN To Present at the Credit Suisse Healthcare ConferencePrinter Friendly Version
October 28, 2009POZEN Reports Third Quarter 2009 ResultsPrinter Friendly Version
October 27, 2009Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy AdultsPrinter Friendly Version
October 27, 2009Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxenPrinter Friendly Version
October 19, 2009Patients Taking VIMOVO(TM) Showed Decrease in incidence of NSAID Associated UlcersPrinter Friendly Version
October 16, 2009AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO™Printer Friendly Version
October 14, 2009POZEN Announces October 28, 2009 Webcast of Third Quarter 2009 ResultsPrinter Friendly Version
September 30, 2009POZEN Inc. Announces Federal District Court Grants Motion to Dismiss Securities Class Action LawsuitPrinter Friendly Version
September 14, 2009POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial OfficerPrinter Friendly Version
September 09, 2009POZEN To Present at the UBS Global Life Sciences ConferencePrinter Friendly Version
August 31, 2009POZEN Announces FDA Acceptance of NDA For VIMOVO(TM)Printer Friendly Version
August 27, 2009POZEN To Present at the Thomas Weisel Partners 2009 Healthcare ConferencePrinter Friendly Version
July 28, 2009POZEN Reports Second Quarter 2009 ResultsPrinter Friendly Version
July 22, 2009POZEN To Present at the 2009 BMO Capital Markets Focus on Healthcare ConferencePrinter Friendly Version
July 14, 2009POZEN Announces July 28, 2009 Webcast of Second Quarter 2009 ResultsPrinter Friendly Version
June 30, 2009POZEN Submits New Drug Application For VIMOVO(TM) (PN 400)Printer Friendly Version
June 09, 2009POZEN Announces Election of Angela M. Larson to Board of DirectorsPrinter Friendly Version
May 13, 2009POZEN Receives Decision from AstraZeneca to File PN 400 NDAPrinter Friendly Version
April 30, 2009POZEN Reports First Quarter 2009 ResultsPrinter Friendly Version
April 16, 2009POZEN Announces April 30, 2009 Webcast of First Quarter 2009 ResultsPrinter Friendly Version
March 19, 2009POZEN To Present at the Citi Annual Biotech DayPrinter Friendly Version
March 04, 2009POZEN to Present at the Cowen and Company 29th Annual Healthcare ConferencePrinter Friendly Version
February 25, 2009POZEN Reports Fourth Quarter and Year End 2008 ResultsPrinter Friendly Version
February 11, 2009POZEN Announces February 25, 2009 Webcast of Fourth Quarter and Year End 2008 ResultsPrinter Friendly Version
January 29, 2009POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary EndpointPrinter Friendly Version